Vertex Pharmaceuticals Incorporated (VRTX) Turns Up the Heat on Bears

Vertex Pharmaceuticals Incorporated's (VRTX) cystic fibrosis drug got the green light from the FDA

Jul 2, 2015 at 1:40 PM
facebook twitter linkedin


Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares shot higher today -- but are currently halted at $130.90 -- on news that the company's cystic fibrosis therapy, Orkambi, received Food and Drug Administration (FDA) approval. With its intraday lead approaching 4%, the stock has advanced 32.5% year-over-year -- though it's struggled in recent months in the $130-$133 neighborhood. Amid this recent churn, option traders have gravitated toward long puts.

Diving right in, during the last 10 days at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), speculators have bought to open 1.36 puts for every call. This ratio ranks in the 82nd percentile of its annual range, suggesting traders have bought to open puts over calls at a faster-than-usual pace lately.

Further reflecting this bias toward puts is VRTX's Schaeffer's put/call open interest ratio (SOIR) of 1.31. Not only does this SOIR indicate short-term put open interest outweighs call open interest, but it also rests above 79% of comparable readings from the previous 12 months.

Analysts are tilted in a skeptical direction, as well. Over half of the brokerages covering Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) have doled out tepid "hold" ratings. What's more, the stock's average 12-month price target of $140.10 is just 7% above the current perch -- though it does represent uncharted territory for VRTX.
 

If you are not making money with options, you aren’t buying options like this…

There is no options strategy that more perfectly approaches trading the fastest moving and most volatile stocks available in the marketplace than this one. In fact, there is no strategy that better utilizes put options for optimal returns and a real trading edge over other traders in the exact same market. New options traders fail out at an incredible rate without proper trade research, execution timing, and option picking. Capitalize on Schaeffer’s 100+ years of options trading excellence with the most coveted product launch in company history. Don't waste another second... join us right now before the next round of trades are released!

Schaeffer's Investment Research Master Portfolio Trial
 


 


 
Special Offers from Schaeffer's Trading Partners